Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open-Label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of BLYG8824A Administered Intravenously In Patients With Locally Advanced Or Metastatic Colorectal Cancer
This is a non-randomised trial with two experimental stages. In the Dose Escalation Stage, participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD). In the Dose Expansion Stage, once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial. BLYG8824A will be administered at a flat dose independent of body weight.